William Hilson
Chairman at Diamond Therapeutics, Inc.
William Hilson active positions
Companies | Position | Start | End |
---|---|---|---|
Cronos Growing Co., Inc.
Cronos Growing Co., Inc. Real Estate DevelopmentFinance Cronos Growing Co., Inc. provides cannabis products. It specializes in cannabis farming, cannabis cultivation and extraction products. The company is headquartered in Toronto, Canada. | Director/Board Member | - | - |
Diamond Therapeutics, Inc.
Diamond Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Diamond Therapeutics, Inc. is a Canadian clinical-stage drug development company founded in 2018 by Judy Blumstock. The company is based in an undisclosed location and is focused on developing safe, FDA, EMA, and Health Canada approved therapies for neuropsychiatric conditions. The company is developing sub-perceptual, non-hallucinogenic, psychedelic-based treatments that hold potential for use across a broad patient cohort, with the goal of maximizing the positive impact better drugs can have on the mental health crisis. Diamond's mission is to develop new and better therapies for mental health conditions by unlocking the promise of psychedelic compounds. | Chairman | - | - |
Silvermine Arts Center | Director/Board Member | - | - |
Career history of William Hilson
Former positions of William Hilson
Companies | Position | Start | End |
---|---|---|---|
MERCK KGAA | Corporate Officer/Principal | - | - |
Serono SA
Serono SA Pharmaceuticals: MajorHealth Technology Serono SA develops products to fight debilitating diseases and other pharmaceutical products. The company has eight biotechnology products on the market and a strong pipeline based on both proteins and small molecules. It's four main Therapeutics Areas are: Reproductive Health, Multiple Sclerosis, Growth & Metabolism, and Dermatology. It focuses on recombinant genetic engineering to develop drugs. The firm also focuses on neurological, metabolic, and human growth disorders. Other products include treatments for growth hormone deficiency, and AIDS-related wasting. The company is headquarterd in Geneva, Switzerland. | Corporate Officer/Principal | - | - |
CRONOS GROUP INC. | Director of Finance/CFO | 06/10/2016 | 15/04/2019 |
Corporate Officer/Principal | 15/04/2019 | - |
Training of William Hilson
University of Western Ontario | Graduate Degree |
University of Toronto | Undergraduate Degree |
Statistics
International
Canada | 6 |
Germany | 2 |
Switzerland | 2 |
Operational
Corporate Officer/Principal | 3 |
Director/Board Member | 2 |
Director of Finance/CFO | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 3 |
Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
CRONOS GROUP INC. | Health Technology |
MERCK KGAA | Health Technology |
Private companies | 4 |
---|---|
Serono SA
Serono SA Pharmaceuticals: MajorHealth Technology Serono SA develops products to fight debilitating diseases and other pharmaceutical products. The company has eight biotechnology products on the market and a strong pipeline based on both proteins and small molecules. It's four main Therapeutics Areas are: Reproductive Health, Multiple Sclerosis, Growth & Metabolism, and Dermatology. It focuses on recombinant genetic engineering to develop drugs. The firm also focuses on neurological, metabolic, and human growth disorders. Other products include treatments for growth hormone deficiency, and AIDS-related wasting. The company is headquarterd in Geneva, Switzerland. | Health Technology |
Cronos Growing Co., Inc.
Cronos Growing Co., Inc. Real Estate DevelopmentFinance Cronos Growing Co., Inc. provides cannabis products. It specializes in cannabis farming, cannabis cultivation and extraction products. The company is headquartered in Toronto, Canada. | Finance |
Diamond Therapeutics, Inc.
Diamond Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Diamond Therapeutics, Inc. is a Canadian clinical-stage drug development company founded in 2018 by Judy Blumstock. The company is based in an undisclosed location and is focused on developing safe, FDA, EMA, and Health Canada approved therapies for neuropsychiatric conditions. The company is developing sub-perceptual, non-hallucinogenic, psychedelic-based treatments that hold potential for use across a broad patient cohort, with the goal of maximizing the positive impact better drugs can have on the mental health crisis. Diamond's mission is to develop new and better therapies for mental health conditions by unlocking the promise of psychedelic compounds. | Health Technology |
Silvermine Arts Center |
- Stock Market
- Insiders
- William Hilson
- Experience